Equity Overview
Price & Market Data
Price: $2.14
Daily Change: +$0.01 / 0.47%
Range: $2.02 - $2.19
Market Cap: $92,488,448
Volume: 291,565
Performance Metrics
1 Week: 16.94%
1 Month: -6.96%
3 Months: -36.87%
6 Months: -58.85%
1 Year: -89.03%
YTD: -42.78%
Company Details
Employees: 112
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.